{"id":"https://openalex.org/W3045364765","doi":"https://doi.org/10.1097/qai.0000000000002454","title":"Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance","display_name":"Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance","publication_year":2020,"publication_date":"2020-07-23","ids":{"openalex":"https://openalex.org/W3045364765","doi":"https://doi.org/10.1097/qai.0000000000002454","mag":"3045364765","pmid":"https://pubmed.ncbi.nlm.nih.gov/32701823"},"language":"en","primary_location":{"id":"doi:10.1097/qai.0000000000002454","doi":"https://doi.org/10.1097/qai.0000000000002454","is_oa":false,"landing_page_url":"https://doi.org/10.1097/qai.0000000000002454","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082977790","display_name":"Rima K Acosta","orcid":"https://orcid.org/0000-0002-0255-9487","observed_orcids":["https://orcid.org/0000-0002-0255-9487"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rima K. Acosta","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","All authors are employees and stock holders of Gilead Sciences, Inc","Rima K. Acosta, BS, Clinical Virology, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404 (e-mail: [email\u00a0protected])"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Rima K. Acosta, BS, Clinical Virology, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404 (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046334669","display_name":"Madeleine Willkom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madeleine Willkom","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080996117","display_name":"Kristen N. Andreatta","orcid":"https://orcid.org/0009-0004-7201-533X","observed_orcids":["https://orcid.org/0009-0004-7201-533X"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen Andreatta","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100387591","display_name":"Hui Liu","orcid":"https://orcid.org/0000-0002-5531-3640","observed_orcids":["https://orcid.org/0000-0002-5531-3640"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Liu","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063608706","display_name":"Ross Martin","orcid":"https://orcid.org/0000-0003-2105-4748","observed_orcids":["https://orcid.org/0000-0003-2105-4748"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ross Martin","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007172147","display_name":"Aiyappa Parvangada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aiyappa Parvangada","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026987150","display_name":"Hal Martin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hal Martin","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103997961","display_name":"Sean E Collins","orcid":"https://orcid.org/0000-0001-5641-8332","observed_orcids":["https://orcid.org/0000-0001-5641-8332"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Collins","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030772735","display_name":"Kirsten White","orcid":"https://orcid.org/0000-0002-5576-5196","observed_orcids":["https://orcid.org/0000-0002-5576-5196"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kirsten L. White","raw_affiliation_strings":["All authors are employees and stock holders of Gilead Sciences, Inc","Gilead Sciences, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"All authors are employees and stock holders of Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5082977790"],"corresponding_institution_ids":["https://openalex.org/I4210140816"],"apc_list":null,"apc_paid":null,"fwci":0.5572,"has_fulltext":false,"cited_by_count":36,"citation_normalized_percentile":{"value":0.81746432,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"85","issue":"3","first_page":"363","last_page":"371"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bictegravir-emtricitabine-tenofovir-alafenamide","display_name":"bictegravir/emtricitabine/tenofovir alafenamide","score":0.9649999737739563},{"id":"https://openalex.org/keywords/dolutegravir","display_name":"dolutegravir","score":0.9769999980926514},{"id":"https://openalex.org/keywords/tenofovir-alafenamide","display_name":"tenofovir alafenamide","score":0.8769999742507935},{"id":"https://openalex.org/keywords/tenofovir-disoproxil-fumarate","display_name":"tenofovir disoproxil fumarate","score":0.9520000219345093},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.7049999833106995},{"id":"https://openalex.org/keywords/antiretroviral-therapy-switching","display_name":"antiretroviral therapy switching","score":0.7329999804496765},{"id":"https://openalex.org/keywords/viral-blips","display_name":"viral blips","score":0.5609999895095825},{"id":"https://openalex.org/keywords/virologic-failure","display_name":"virological failure","score":0.7649999856948853},{"id":"https://openalex.org/keywords/treatment-emergent-resistance","display_name":"treatment-emergent resistance","score":0.7609999775886536},{"id":"https://openalex.org/keywords/thymidine-analogue-mutations","display_name":"thymidine analogue mutations","score":0.8209999799728394},{"id":"https://openalex.org/keywords/hiv-1-rna-suppression","display_name":"HIV-1 RNA suppression","score":0.40799999237060547}],"concepts":[{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.8734979629516602},{"id":"https://openalex.org/C2779778239","wikidata":"https://www.wikidata.org/wiki/Q422604","display_name":"Emtricitabine","level":5,"score":0.7457172870635986},{"id":"https://openalex.org/C2911190787","wikidata":"https://www.wikidata.org/wiki/Q22075912","display_name":"Tenofovir alafenamide","level":5,"score":0.6880208849906921},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.6443420648574829},{"id":"https://openalex.org/C182707283","wikidata":"https://www.wikidata.org/wiki/Q7315622","display_name":"Resistance mutation","level":5,"score":0.6407535076141357},{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.6073702573776245},{"id":"https://openalex.org/C2777302000","wikidata":"https://www.wikidata.org/wiki/Q412251","display_name":"Integrase inhibitor","level":5,"score":0.529219925403595},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.4920770525932312},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4232717752456665},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3599165081977844},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.33495157957077026},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.29479873180389404},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2334815263748169},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.15695896744728088},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.09760484099388123},{"id":"https://openalex.org/C49105822","wikidata":"https://www.wikidata.org/wiki/Q176996","display_name":"Polymerase chain reaction","level":3,"score":0.09679454565048218},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000099226","descriptor_name":"Dolutegravir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015999","descriptor_name":"Multivariate Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016015","descriptor_name":"Logistic Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/qai.0000000000002454","doi":"https://doi.org/10.1097/qai.0000000000002454","is_oa":false,"landing_page_url":"https://doi.org/10.1097/qai.0000000000002454","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"pmid:32701823","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32701823","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of acquired immune deficiency syndromes (1999)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8100000023841858,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W1754590933","https://openalex.org/W1996968222","https://openalex.org/W2026323517","https://openalex.org/W2032979759","https://openalex.org/W2044864734","https://openalex.org/W2072661867","https://openalex.org/W2094811879","https://openalex.org/W2096290753","https://openalex.org/W2102741140","https://openalex.org/W2119254819","https://openalex.org/W2123055341","https://openalex.org/W2125377515","https://openalex.org/W2149330759","https://openalex.org/W2151983644","https://openalex.org/W2314470608","https://openalex.org/W2329137787","https://openalex.org/W2523305619","https://openalex.org/W2586083164","https://openalex.org/W2752494178","https://openalex.org/W2753489952","https://openalex.org/W2807278249","https://openalex.org/W2807835948","https://openalex.org/W2807931585","https://openalex.org/W2808133151","https://openalex.org/W2808227723","https://openalex.org/W2912155276","https://openalex.org/W2915372808","https://openalex.org/W2917536757","https://openalex.org/W2944376193","https://openalex.org/W2960940959","https://openalex.org/W2969479109","https://openalex.org/W2980839050","https://openalex.org/W2998080559","https://openalex.org/W2998855521","https://openalex.org/W3009494891","https://openalex.org/W3022361442","https://openalex.org/W4244459571","https://openalex.org/W6759321565","https://openalex.org/W6765896158"],"related_works":["https://openalex.org/W2969479109","https://openalex.org/W3042726352","https://openalex.org/W3157019581","https://openalex.org/W2917536757","https://openalex.org/W4395465591","https://openalex.org/W4400454571","https://openalex.org/W4285734539","https://openalex.org/W4293507321","https://openalex.org/W4407872582","https://openalex.org/W3120237300"],"abstract_inverted_index":{"BACKGROUND:":[0],"Study":[1],"4030":[2],"was":[3,34,41,67,150,232],"a":[4],"phase":[5],"3,":[6],"randomized,":[7],"double-blinded":[8],"study":[9,112,221],"of":[10,74,76,119,166,182,186,230],"565":[11],"HIV-1":[12,53,102],"RNA-suppressed":[13],"participants":[14,120,203,206],"switching":[15,240],"to":[16,107,220,241],"bictegravir/emtricitabine/tenofovir":[17],"alafenamide":[18],"(B/F/TAF)":[19],"or":[20,64,98,137,243],"dolutegravir":[21],"(DTG)+F/TAF.":[22],"Nucleoside":[23],"reverse":[24],"transcriptase":[25],"inhibitor":[26,31],"(NRTI),":[27],"non-NRTI,":[28],"and":[29,56,89,142,170,179,248],"protease":[30,171],"resistance":[32,48,91,210,219],"(-R)":[33],"allowed,":[35],"but":[36],"integrase":[37,156],"strand":[38,157],"transfer":[39,158],"inhibitor-R":[40,159,172],"excluded.":[42],"Here,":[43],"we":[44],"describe":[45],"the":[46],"detailed":[47],"analysis.":[49],"METHODS:":[50],"Historical":[51],"plasma":[52],"RNA":[54,103],"genotypes":[55,60],"baseline":[57,122,226],"proviral":[58],"DNA":[59],"were":[61,80,161,174,189,198,251],"analyzed.":[62],"Documented":[63],"investigator-suspected":[65],"NRTI-R":[66,127,147],"grouped":[68],"for":[69,209],"stratification":[70],"into":[71],"3":[72],"categories":[73],"level":[75],"resistance.":[77,259],"Viral":[78],"blips":[79,197],"assessed":[81],"through":[82,194],"week":[83,94,195],"48.":[84],"Virologic":[85],"failures":[86],"had":[87,121],"genotypic":[88,123],"phenotypic":[90],"analyses":[92],"at":[93],"48,":[95],"confirmed":[96],"failure,":[97],"last":[99],"visit,":[100],"if":[101],"did":[104],"not":[105],"resuppress":[106],"<50":[108],"copies/mL":[109],"while":[110],"on":[111],"drug.":[113],"RESULTS:":[114],"In":[115],"total,":[116],"83%":[117],"(470/565)":[118],"data":[124],"available":[125],"with":[126,135,145,225,256],"detected":[128],"in":[129,152,163,176,191,200,213],"24%":[130],"(138/565),":[131],"including":[132],"5%":[133],"(30/565)":[134],"K65R/E/N":[136],"\u22653":[138],"thymidine":[139],"analog":[140],"mutations":[141,160,173],"19%":[143],"(108/565)":[144],"other":[146],"mutations.":[148],"M184V/I":[149],"present":[151,175],"14%":[153],"(81/565).":[154],"Pre-existing":[155],"found":[162],"4%":[164],"(20/565)":[165],"participants.":[167,183],"Primary":[168],"non-NRTI-R":[169],"21%":[177],"(118/565)":[178],"7%":[180],"(38/565)":[181],"High":[184],"rates":[185],"viral":[187],"suppression":[188,236],"maintained":[190,235],"all":[192],"groups":[193],"48;":[196],"observed":[199],"only":[201],"15":[202],"(2.7%).":[204],"Three":[205],"met":[207],"criteria":[208],"analysis":[211],"(all":[212],"DTG+F/TAF":[214,244],"arm);":[215],"none":[216],"developed":[217],"treatment-emergent":[218,258],"drugs.":[222],"CONCLUSIONS:":[223],"Participants":[224],"NRTI":[227],"resistance,":[228],"much":[229],"which":[231],"previously":[233],"undocumented,":[234],"48":[237],"weeks":[238],"after":[239],"B/F/TAF":[242],"triple":[245],"therapy.":[246],"Blips":[247],"virologic":[249],"failure":[250],"uncommon":[252],"using":[253],"either":[254],"regimen,":[255],"no":[257]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-07-29T00:00:00"}